Anidulafungin is an antifungal medication developed by the U.S. Food And Drug Administration and initially approved on 21 Feb 2006 for treating serious fungal infections.

Anidulafungin helps to treat certain invasive fungal infections. It is effective against various types of invasive candidiasis, such as candidemia (Candida bloodstream infection) and esophageal candidiasis (fungal infection affecting the esophagus). Invasive candidiasis occurs when candida yeasts enter the bloodstream or other internal organs and cause systemic infections.

Anidulafungin is administered directly into the vein intravenously (IV). It is available as a powder for reconstitution, and a physician will prepare and administer the medication through a vein. The IV infusion is usually given over a period of one to two hours.

The side effects known to occur commonly during the treatment with Anidulafungin are low blood potassium (hypokalaemia), diarrhea, nausea, headache, and vomiting. Some serious side effects also include convulsion (seizure), flushing, rash, pruritus (itching), hot flush, hives, wheezing , coughing, and difficulty of breathing.

This drug is contraindicated in individuals with known hypersensitivity or allergy to it or its component. If you develop liver problems during your treatment with this drug, your doctor may decide to monitor your liver function more closely. Anidulafungin is primarily metabolized in the liver, so it's important to assess liver function regularly, especially in patients with pre-existing liver conditions. Inform your physician, including anesthesiologists, about your treatment with this drug, especially before undergoing surgery or receiving anesthesia. The combination of certain anesthetics with this medication could interact, so it's necessary for medical professionals to be aware of your medication history. 

Pay attention to any unusual symptoms like shortness of breath, breathing difficulties, lightheadedness, or dizziness during your treatment with this drug. If you experience any of these symptoms, contact your physician immediatley. It is unknown whether Anidulafungin is safe for pregnant women, so it is not recommended during pregnancy due to limited data. If a woman of childbearing age is prescribed this drug, it is essential to use effective contraception during the treatment period to avoid pregnancy. The effect of this drug on breastfeeding women is not known. Breastfeeding women should contact their doctor for more advice before taking this medicine.

Anidulafungin is given through intravenous infusion. Some individuals may experience infusion-related reactions, including a rash, hives, itching, or redness at the infusion site. If you notice any of these symptoms during or after the infusion, notify your physician immediately.

1. Pfizer Limited, Electronic medicines compendium (EMC), [Revised on April 2022] [ Accessed on 26th July 2023], https://www.medicines.org.uk/emc/files/pil.454.pdf
2. Roerig, US Food and Drug Administration, [Revised date Feb 2006], [Accessed on 26th July 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021632s002lbl.pdf
3. KD Tripathi, Essentials of Medical Pharmacology, 7th edition, Antifungal drugs, 2013, 790.

The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.